{"id":"W3201084964","doi":"10.1158/1078-0432.ccr-21-1504","title":"First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; University of Texas MD Anderson Cancer Center; National Cancer Institute; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Eli Lilly and Company","keywords":"Gemcitabine; Pancreatic cancer; Cancer; Phases of clinical research; Receptor; Pancreatic disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00123694,0.00157004,0.001423313,0.0002439652,0.0004019112,0.0008957018,0.0006978964,0.0008606046,0.004323177],"category_scores_gemma":[0.0005090674,0.0005336087,0.0008752713,0.000270989,0.0007152662,0.0007553732,0.0003175742,0.002814559,0.001027749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009126107,"about_ca_system_score_gemma":0.00175931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008608822,"about_ca_topic_score_gemma":0.002336948,"domain_scores_codex":[0.9997167,0.000116125,0.00001254736,0.00005384494,0.00002824198,0.00007252181],"domain_scores_gemma":[0.9995777,0.0000464207,0.00007546927,0.00004405044,0.00003712523,0.0002192649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4351231,0.1711241,0.01750481,0.001303381,0.001585525,0.0005713684,0.0005574897,0.003643798,0.2028467,0.0005639907,0.0138598,0.1513158],"study_design_scores_gemma":[0.3037765,0.6586601,0.01429686,0.00003360137,0.0004398366,0.0004091591,0.00008058896,0.001423075,0.01511897,0.0002082199,0.005522461,0.00003057992],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902809,0.001724495,0.0009473656,0.0003843739,0.0001124584,0.00295035,0.001448364,0.0001418203,0.002009782],"genre_scores_gemma":[0.9852314,0.001305079,0.002142391,0.0007964031,0.0001698658,0.00265904,0.003174477,0.0000586725,0.004462743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004323177,"threshold_uncertainty_score":0.01446247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1678955923304999,"score_gpt":0.4950953371301059,"score_spread":0.327199744799606,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}